Navigation Links
InterMune to Release Second Quarter Financial Results on August 4
Date:7/28/2011

BRISBANE, Calif., July 28, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) today announced that it will release its second quarter 2011 financial results on Thursday, August 4, 2011. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day to discuss business highlights and financial results for the second quarter and first six months of 2011.

To access the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 80082950.  To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 80082950.  

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
2. InterMune to Webcast 2011 Analyst Day Presentations
3. InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
4. InterMune to Present at Bank of America Merrill Lynch Health Care Conference
5. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
6. InterMune to Release First Quarter Financial Results on April 28
7. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
8. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
9. InterMune to Release Third Quarter Financial Results on October 28
10. InterMune Sells Danoprevir Rights to Roche for $175 Million
11. InterMune to Present at 2010 Citi Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising ... at the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular ... US earlier this year following FDA approval of a second application for a ...
(Date:5/25/2016)... Portland, Oregon (PRWEB) , ... May 25, 2016 ... ... Base Set features a variety of fracture-specific plating options designed to address fractures ... provide industry-leading fracture fixation solutions. , The Acumed Ankle Plating System 3 is ...
(Date:5/25/2016)... ... ... Lady had been battling arthritis since the age of two and at ... owner Hannah sought the help of Dr Jeff Christiansen of Superior Veterinary Surgical ... and help with the pain of Lady’s arthritis. Dr Christiansen suggested that in conjunction ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for a ... image analysis. The re-branding components include a crisp, refreshed logo and a new ...
Breaking Biology Technology:
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/10/2016)... --> --> ... and Access Management Market by Component (Provisioning, Directory Services, ... Organization Size, by Deployment, by Vertical, and by Region ... market is estimated to grow from USD 7.20 Billion ... a Compound Annual Growth Rate (CAGR) of 12.2% during ...
(Date:3/9/2016)... PALM BEACH GARDENS, Fla. , March 9, ... of identity management authentication and enrollment solutions, today ... proven DigitalPersona ® Altus multi-factor ... enable IT and InfoSec managers to step-up security ... friction.  Washington, DC ...
Breaking Biology News(10 mins):